For individuals with advanced or metastatic non-small cell lung cancer (NSCLC), the primary
treatment is platinum-based doublet chemotherapy. Immune checkpoint inhibitors (ICIs) …

In recent years, immune checkpoint inhibitors have rapidly changed treatment paradigms
and have been pivotal for the treatment of advanced NSCLC patients. However, many …

Lung cancer is a malignant tumor with the highest mortality in the world. The most common
pathological type of lung cancer is non-small cell lung cancer (NSCLC). In recent years …

The treatment landscape of advanced non-small cell lung cancer (NSCLC) has changed
dramatically since the emergence of immune checkpoint inhibitors (ICIs). Although some …

Lung cancer, with non-small cell lung cancer (NSCLC) being the major type, is the second
most common malignancy and the leading cause of cancer-related death globally …

Simple Summary Despite the promising results not all patients with advanced non-small cell
lung cancer benefit from immunotherapy. Immunotherapy may cause severe adverse …

Immunotherapy plays a central role in the treatment of NSCLC and biomarkers predicting
response to ICIs are valuable therapeutic tools. Programmed death-ligand 1 (PD-L1) …

Immunotherapy including immune checkpoint inhibitors (ICIs) has become the backbone of
treatment for most lung cancers with advanced or metastatic disease. In addition, they have …

Immunotherapy has markedly improved the survival rate of patients with non‑small cell lung
cancer (NSCLC) and has introduced a new era in lung cancer treatment. However, not all …

Immunotherapy has markedly improved the survival rate of patients with non–small cell lung
cancer (NSCLC) and has introduced a new era in lung cancer treatment. Although some …